jph08503468a - therapeutic use of chimeric antibody

JP3095175B2

JP3095175B2 JP06512376A JP51237694A JP3095175B2 JP 3095175 B2 JP3095175 B2 JP 3095175B2 JP 06512376 A JP06512376 A JP 06512376A JP 51237694 A JP51237694 A JP 51237694A JP 3095175 B2 JP3095175 B2 JP 3095175B2 Authority JP Japan Prior art keywords antibody cd20 composition cells anti Prior art date 1992-11-13 Legal status (The legal status is an assumption and is

IJMS

Effective adoptive T cell therapy (ACT) comprises the killing of cancer cells through the therapeutic use of transferred T cells One of the main ACT approaches is chimeric antigen receptor (CAR) T cell therapy CAR T cells mediate MHC-unrestricted tumor cell killing by enabling T cells to bind target cell surface antigens through a single-chain variable fragment (scFv) recognition domain

Binding mechanisms of therapeutic antibodies to human CD20

Aug 14 2020Human cluster of differentiation 20 (CD20) is expressed on malignant B cells and is the target of therapeutic antibodies used in cancer immunotherapy Kumar et al now present structures that explain why so-called type I antibodies efficiently activate the complement pathway to kill cells whereas type II antibodies do not Type I antibodies each bind to two CD20 dimers and form

Public Summary of Positive Opinion for Orpahn Designation

The chimeric monoclonal antibody cG250 had not been marketed anywhere worldwide for renal cell carcinoma at the time of submission Orphan drug status has been granted by the United States Food and Drug Administration (FDA) for the cG250 monoclonal antibody to treat renal cell carcinoma

Evolution and Emergence of Therapeutic Monoclonal Antibodies

The development of human antibodies against murine or chimeric mAbs also referred to as an anti-antibody response was one of the most important therapeutic limitations of early mAb therapy As with any drug class development of an immune response against a therapy can affect its efficacy and safety mAbs are no different

Escape from neutralizing antibodies by SARS

Jul 21 2020Neutralizing antibodies elicited by prior infection or vaccination are likely to be key for future protection of individuals and populations against SARS-CoV-2 Moreover passively administered antibodies are among the most promising therapeutic and prophylactic anti-SARS-CoV-2 agents However the degree to which SARS-CoV-2 will adapt to evade neutralizing antibodies is unclear

Monoclonal Antibodies

May 04 2016The suffix -mab is used for monoclonal antibodies antibody fragments and radiolabeled antibodies For polyclonal mixtures of antibodies -pab is used The -pab suffix applies to polyclonal pools of recombinant monoclonal antibodies as opposed to polyclonal antibody preparations isolated from blood

Chimeric Ad5 F35 vector evades anti

Background Adenovirus serotype 5 (Ad5) is a commonly used viral vector for transient delivery of transgenes primarily for vaccination against pathogen and tumor antigens However endemic infections with Ad5 produce virus-specific neutralizing antibodies (NAbs) that limit transgene delivery and constrain target-directed immunity following exposure to Ad5-based vaccines Indeed clinical

UpToDate

Oct 03 2019Chimeric antibodies are generally those in which the Fc part of the immunoglobulin molecule (but not the CDR) is of a human sequence In general chimeric mAbs and humanized antibodies contain 65 and 90 percent human sequence respectively In addition several technologies exist to generate fully humanized antibodies for therapeutic use

Infliximab or Biosimilar Activity and Neutralizing Antibody

Infliximab Neutralizing Antibody Titer Interpretation Not Detected: Not Detected: Sub-therapeutic dose A higher dosage of infliximab or shortening the dosing interval may be appropriate Not Detected: Detected: Likely immune-mediated treatment failure A change to another anti-TNF drug may be appropriate Detected - Below Target* N/A: Sub

What are Therapeutic Antibodies? (with picture)

Jul 16 2020Therapeutic antibodies are man-made substances able to bind to specific proteins on the surface of a cell Most therapeutic antibodies are monoclonal antibodies meaning that they are antibodies produced by clones of a single immune cell Each monoclonal antibody is only able to bind to a single antigen Both of these properties are highly

Chimeric Antigen Receptor (CAR) T

Chimeric antigen receptor T-cell clinical trials have generated impressive results in the early outcomes of CAR T-cell therapy patients with blood cancers In some studies up to 90 percent of children and adults with B-ALL whose disease had either relapsed multiple times or failed to respond to standard therapies achieved remission after

Therapeutic AntibodiesAntibody Therapy

Therapeutic antibodies specifically monoclonal antibodies can activate repress or alter endogenous immune responses to specific cells or molecules Antibody-based drugs are revolutionizing the treatment of cancer inflammatory and autoimmune disease and many other types of disease

The clinical pharmacology of therapeutic monoclonal antibodies

Jul 19 2004Seventeen monoclonal antibodies are currently approved in the United States for therapeutic use in organ transplantation percutaneous coronary intervention prophylaxis of respiratory syncytial virus disease rheumatoid arthritis Crohn's disease asthma chronic lymphocytic leukemia acute myeloid leukemia non‐Hodgkin's lymphoma breast cancer and colorectal cancer

Chimeric antigen receptor T cell therapy for multiple

Chimeric antigen receptor (CAR) T cell therapy is a new cancer immunotherapy targeting cancer-specific cell surface antigen CD19-CAR T cells have been already shown to be very effective to B cell leukemia/lymphoma Now many researchers are developing CAR T cells for multiple myeloma CAR T cells targeting B cell maturation antigen (BCMA) showed promising efficacy in early phase clinical trials

Humanized antibody

Humanized antibodies are antibodies from non-human species whose protein sequences have been modified to increase their similarity to antibody variants produced naturally in humans The process of humanization is usually applied to monoclonal antibodies developed for administration to humans (for example antibodies developed as anti-cancer drugs) ) Humanization can be necessary when the

Escape from neutralizing antibodies by SARS

Jul 21 2020Neutralizing antibodies elicited by prior infection or vaccination are likely to be key for future protection of individuals and populations against SARS-CoV-2 Moreover passively administered antibodies are among the most promising therapeutic and prophylactic anti-SARS-CoV-2 agents However the degree to which SARS-CoV-2 will adapt to evade neutralizing antibodies is unclear

How mRNA therapeutics are entering the monoclonal antibody

Feb 22 2019In 1975 Milstein and Khler revolutionized the medical world with the development of the hybridoma technique to produce monoclonal antibodies Since then monoclonal antibodies have entered almost every branch of biomedical research Antibodies are now used as frontline therapeutics in highly divergent indications ranging from autoimmune disease over allergic asthma to cancer

Five computational developability guidelines for

Mar 05 2019Immunogenicity instability self-association high viscosity polyspecificity or poor expression can all preclude an antibody from becoming a therapeutic Early identification of these negative characteristics is essential Akin to the Lipinski guidelines which measure druglikeness in small molecules our Therapeutic Antibody Profiler highlights antibodies that possess characteristics that

Antibody conjugation and formulation

After a clinical target has been determined and an antibody has been selected it is necessary to formulate the antibody therapeutic prior to clinical use Antibody formulation is a complex optimization process utilizing unique pharmaceutical additives to address the varying demands of storage freeze–thaw and route of administration

List of therapeutic monoclonal antibodies

This is a list of therapeutic diagnostic and preventive monoclonal antibodies antibodies that are clones of a single parent cell When used as drugs the International Nonproprietary Names (INNs) end in -mab The remaining syllables of the INNs as well as the column Source are explained in Nomenclature of monoclonal antibodies

Evolution and Emergence of Therapeutic Monoclonal Antibodies

The development of human antibodies against murine or chimeric mAbs also referred to as an anti-antibody response was one of the most important therapeutic limitations of early mAb therapy As with any drug class development of an immune response against a therapy can affect its efficacy and safety mAbs are no different

Fc

Other therapeutic antibodies including a HER2-targeted humanized IgG1 trastuzumab a PSMA-targeted humanized IgG1 huJ591 an EGFR-targeted chimeric antibody cetuximab were obtained from the pharmacy at Memorial Sloan Kettering Cancer Center and modified to generate immunoconjugates that were radiolabeled with zirconium-89 (89 Zr t 1/2 = 78 4

Introduction to Diagnostic and Therapeutic Monoclonal

Nov 16 20124 Describe the location and functional purpose of antibody structural components 5 Differentiate among the categories: polyclonal monoclonal murine chimeric humanized and human antibodies 6 Discuss the advantages and disadvantages in human use of murine chimeric humanized and human antibodies 7